Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is conducting a Phase ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is ...

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...

Eli Lilly's oral pill, orforglipron, helped maintain weight loss in patients switching from injectable versions of GLP-1 ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly (NYSE:LLY) shares rose about 2% on early Thursday after the company said a pivotal study for its experimental ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...